# ASP2138

Source: https://onco.cc/drugs/asp2138/  
OnCo record `asp2138` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3.

## Summary

ASP2138 is a bispecific antibody developed by Astellas Pharma Global Development. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673887 (A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer), in gastric & gastro-oesophageal junction cancer. The largest, NCT07673887, plans to enrol 570 participants with primary completion expected 2031-02-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously.

## Sources

- ClinicalTrials.gov: trials of ASP2138: https://clinicaltrials.gov/search?intr=ASP2138
- Sponsor pipeline page: https://newsroom.astellas.com/2026-08-25-astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma

## Connected records

- cancers: [Claudin 18.2-positive gastric cancer](https://onco.cc/cancers/gastric-cldn18-2-positive/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- targets: [CD3](https://onco.cc/targets/cd3/), [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Astellas](https://onco.cc/companies/astellas/)
- trials: [A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer](https://onco.cc/trials/nct07673887/)

---
JSON: https://onco.cc/api/v1/entities/asp2138.json